X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TORRENT PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. TORRENT PHARMA FRESENIUS KABI ONCO./
TORRENT PHARMA
 
P/E (TTM) x 22.1 44.8 49.4% View Chart
P/BV x 3.1 6.1 51.2% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 FRESENIUS KABI ONCO.   TORRENT PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TORRENT PHARMA
Mar-18
FRESENIUS KABI ONCO./
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,550 11.4%   
Low Rs791,144 6.9%   
Sales per share (Unadj.) Rs37.7354.7 10.6%  
Earnings per share (Unadj.) Rs5.140.1 12.7%  
Cash flow per share (Unadj.) Rs6.764.2 10.5%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs42.5273.1 15.6%  
Shares outstanding (eoy) m158.23169.22 93.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.8 88.9%   
Avg P/E ratio x25.033.6 74.3%  
P/CF ratio (eoy) x18.921.0 90.3%  
Price / Book Value ratio x3.04.9 60.7%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m20,135227,897 8.8%   
No. of employees `0001.214.7 7.8%   
Total wages/salary Rs m70311,353 6.2%   
Avg. sales/employee Rs Th5,176.24,083.0 126.8%   
Avg. wages/employee Rs Th610.4772.3 79.0%   
Avg. net profit/employee Rs Th699.6461.3 151.6%   
INCOME DATA
Net Sales Rs m5,96360,021 9.9%  
Other income Rs m182,988 0.6%   
Total revenues Rs m5,98163,009 9.5%   
Gross profit Rs m1,43013,493 10.6%  
Depreciation Rs m2584,086 6.3%   
Interest Rs m-263,085 -0.8%   
Profit before tax Rs m1,2169,310 13.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,529 13.5%   
Profit after tax Rs m8066,781 11.9%  
Gross profit margin %24.022.5 106.7%  
Effective tax rate %28.127.2 103.6%   
Net profit margin %13.511.3 119.6%  
BALANCE SHEET DATA
Current assets Rs m5,10252,623 9.7%   
Current liabilities Rs m2,38552,022 4.6%   
Net working cap to sales %45.61.0 4,545.3%  
Current ratio x2.11.0 211.4%  
Inventory Days Days150120 125.5%  
Debtors Days Days11376 148.6%  
Net fixed assets Rs m5,14885,016 6.1%   
Share capital Rs m158846 18.7%   
"Free" reserves Rs m6,55645,376 14.4%   
Net worth Rs m6,73246,222 14.6%   
Long term debt Rs m95241,115 2.3%   
Total assets Rs m10,388142,432 7.3%  
Interest coverage x-45.84.0 -1,139.3%   
Debt to equity ratio x0.10.9 15.9%  
Sales to assets ratio x0.60.4 136.2%   
Return on assets %7.56.9 108.4%  
Return on equity %12.014.7 81.6%  
Return on capital %14.614.2 102.9%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29814,580 36.3%   
Fx outflow Rs m1,7723,600 49.2%   
Net fx Rs m3,52510,980 32.1%   
CASH FLOW
From Operations Rs m1,2748,942 14.2%  
From Investments Rs m-1,204-47,070 2.6%  
From Financial Activity Rs m-19634,174 -0.6%  
Net Cashflow Rs m-126-3,655 3.5%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 7.0 4.3%  
FIIs % 9.6 12.6 76.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.8 103.4%  
Shareholders   42,599 26,511 160.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS